Generate Biomedicines closed at $14.16 on Nov 4, up 2.24%, 18.9% below its highest close since Sep 11. Volume of 636.7K shares was 0.62× its 20-day average (below normal).
Split-adjusted performance: +2.6% over one month.
In the quarter ended Jun 30, 2026, revenue was $6.31M, with a net margin of -1065.2%.
Short interest was 8.9M shares at the Oct 15 settlement, up 20.4% from the prior report (15.4% of float, 8.0 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| GENBGenerate Biomedicines | $14.16 | +2.24% | — | — | −1065.2% | — | $1.82B | |
| BRVEBraveheart Bio | $20.11 | −6.01% | — | — | — | — | $1.81B | Compare |
| PGENPrecigen | $5.06 | −3.71% | +14.9% | +6322.7% | 36.5% | — | $1.81B | Compare |
| SLSSELLAS Life Sciences Group | $9.14 | +3.04% | +77.5% | — | — | — | $1.85B | Compare |
| ZBIOZenas BioPharma | $28.46 | +0.28% | +36.6% | — | −11145.6% | — | $1.85B | Compare |
| STOKStoke Therapeutics | $27.45 | +1.70% | −17.5% | +5.9% | −654.3% | — | $1.77B | Compare |
| AGIOAgios Pharmaceuticals | $31.38 | +0.58% | +16.3% | +259.3% | −225.1% | — | $1.87B | Compare |
| NRIXNurix Therapeutics | $15.95 | −38.23% | −5.5% | +8426.3% | 81.7% | 5.9 | $1.74B | Compare |
| XERSXeris Biopharma Holdings | $10.46 | +1.06% | +64.2% | +28.7% | −33.8% | — | $1.91B | Compare |
No recent articles focused on Generate Biomedicines. 6 articles mention it in passing.
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
